Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

77.8%

7 terminated/withdrawn out of 9 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

7 withdrawn

Enrollment Performance

Analytics

Phase 2

8(88.9%)

Early Phase 1

1(11.1%)

9Total

Phase 2(8)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03146637Phase 2Unknown

Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Role: lead

NCT03554395Phase 2Withdrawn

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer

Role: collaborator

NCT03501056Phase 2Withdrawn

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer

Role: collaborator

NCT03540199Phase 2Withdrawn

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

Role: collaborator

NCT03524274Phase 2Withdrawn

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer

Role: collaborator

NCT03484962Phase 2Withdrawn

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer

Role: collaborator

NCT03509298Phase 2Withdrawn

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer

Role: collaborator

NCT03524261Phase 2Withdrawn

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer

Role: collaborator

NCT04076137Early Phase 1Unknown

Targeted T-cell Therapy in Solid Tumors

Role: lead

All 9 trials loaded